Introduction {#sec1_1}
============

Intravitreal vascular endothelial growth factor (VEGF) inhibitors are the standard treatment for subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) \[[@B1], [@B2]\]. Though the original dosing regimen studied involved monthly injections, recently it has been observed that monthly follow-up with as needed treatment decreased the number of injections without sacrificing the gain in visual acuity \[[@B3], [@B4], [@B5]\]. Currently, most retina specialists employ optical coherence tomography (OCT) to evaluate CNV lesions and determine if additional VEGF inhibition is needed. Although OCT has become the mainstay for retinal imaging, fluorescein angiography (FA) is still important in the diagnosis and monitoring of retinal pathologies such as CNV, especially when geographic atrophy (GA) develops after CNV regression \[[@B6], [@B7]\].

We conducted a retrospective study to evaluate the dynamic changes seen on FA in 3 patients who had undergone serial FA imaging over 48 months of treatment with intravitreal (IVT) VEGF inhibitors for neovascular AMD.

Materials and Methods {#sec1_2}
=====================

This study was approved by the Johns Hopkins Institutional Review Board, which granted a waiver of consent for access to medical records for all persons included in the study. Retrospective chart review was performed for patients who had routine fluorescein angiograms and OCT performed as they were being treated with intravitreal VEGF inhibitors for neovascular AMD. Three sample cases are described below.

Case Reports {#sec1_3}
============

Case 1 {#sec2_1}
------

Patient 1 is a 75-year-old man who presented with decreased vision. Initially, his visual acuity was found to be 20/ 63 in the left eye with subfoveal CNV due to AMD. Baseline FA revealed a small subretinal hemorrhage and leakage from classic CNV (**fig. [1a](#F1){ref-type="fig"}**). One month after receiving an IVT injection with ranibizumab (RBZ), the CNV lesion decreased in size (fig. [1b](#F1){ref-type="fig"}), and it continued to regress and show decreasing amounts of leakage at months 3 and 6, stabilized at month 9, and increased in leakage at month 12 (fig. [1c--f](#F1){ref-type="fig"}) as the patient received additional RBZ on an as needed basis depending on CNV activity seen on either FA and/or OCT. At month 47 and after a total of 16 ranibizumab injections, the CNV had completely regressed. However, GA had developed over the fovea resulting in a visual acuity (VA) of 20/250 (fig. [1g](#F1){ref-type="fig"}).

Case 2 {#sec2_2}
------

Patient 2 is an 85-year-old man who presented with a VA of 20/80 in his right eye and subfoveal occult CNV due to AMD. On presentation, the CNV lesion was greater than 9 disc areas. One month after treatment with ranibizumab, the CNV had regressed and there was decreased leakage on FA. There was continued CNV regression through months 3, 6, 9 and 12 as the patient received additional RBZ on an as needed basis. At month 48 and after a total of 23 RBZ injections, there was no CNV leakage remaining, and the VA was 20/50, but some extrafoveal GA had developed.

Case 3 {#sec2_3}
------

Patient 3 is an 80-year-old woman who presented with a VA of 20/125 and subfoveal occult CNV due to AMD in the left eye. At the initial visit, there was subretinal hemorrhage and leakage from CNV (**fig. [2a](#F2){ref-type="fig"}**). After 2 RBZ treatments, there was regression of the CNV lesion at month 2 (fig. [2b](#F2){ref-type="fig"}), but leakage returned through month 12 (fig. [2c--e](#F2){ref-type="fig"}). This patient was followed up for a total of 57 months, during which she received 20 RBZ injections and 2 bevacizumab injections. At her most recent visit, there was foveal GA with no CNV leakage, and her VA was 20/125 (fig. [2f](#F2){ref-type="fig"}).

Discussion {#sec1_4}
==========

Both FA and OCT images are able to monitor CNV activity after VEGF inhibition \[[@B8]\]. However, despite OCT being more commonly used today to monitor CNV lesions, FA and OCT have different benefits and limitations. OCT allows for visualization of the retina to document intraretinal or subretinal fluid and elevation of the retinal pigment epithelium (RPE) associated with CNV. FA visualizes the actual extent and size of the CNV lesion and documents leakage associated with it. Although spectral domain- (SD) OCT can sample a large area of the retina with high resolution, it still cannot document the extent of CNV seen on FA \[[@B9]\]. FA can truly document both the size of the CNV lesion and regression of it after treatment with VEGF inhibition, and aid in the diagnosis of geographic atrophy. More recently, ophthalmologists have also been employing SD-OCT for identifying areas of geographic atrophy that could be responsible for poor visual outcomes after anti-VEGF therapy.

Few studies have described long-term changes in CNV lesions with FA after VEGF inhibition. This case series documents CNV regression induced by anti-VEGF therapy. In addition, it documents the development of atrophy in the macula after CNV regression. The GA may be due to the natural history of the disease or it may be accelerated by CNV regression by anti-VEGF therapy. Rosenfeld et al. \[[@B10]\] evaluated causes of vision loss after anti-VEGF therapy and also demonstrated that RPE changes and atrophy were common causes of vision loss after long-term use of RBZ for neovascular AMD. Their study evaluated 71 eyes that lost at least 15 letters of VA over a 24-month period, and they found that RPE atrophy and/or abnormalities were the most common causes of visual loss among these patients. Additional studies of OCT and FA would be helpful to identify if chronic anti-VEGF therapy increases the risk of GA. In addition to OCT, FA is still an important tool for monitoring CNV activity after VEGF inhibition and for documenting CNV regression and the development of atrophy in the macula.
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![Late-phase fluorescein angiograms from a patient treated with ranibizumab on an as needed basis over 47 months. The CNV lesion measured 2 disc areas at baseline (**a**). After the initial ranibizumab treatment, the CNV lesion decreased in size at month 1 (**b**) month 3 (**c**) and month 6 (**d**), maintained this size through month 9 (**e**), and increased at month 12 (**f**). At 47 months (**g**), there was no CNV activity but geographic atrophy had developed.](cop-0003-0384-g01){#F1}

![Late-phase fluorescein angiograms from a patient treated with bevacizumab at baseline and treated with either bevacizumab or ranibizumab on an as needed basis for 57 months. The CNV lesion measured 1--2 disc areas at baseline (**a**). The lesion decreased in size slightly at month 1 (**b**) and then leaked more at month 5 (**c**), month 9 (**d**) and month 12 (**e**). Over 57 months, the CNV activity completely regressed though geographic atrophy had developed (**f**).](cop-0003-0384-g02){#F2}
